Ginkgo Bioworks Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production

Reuters

Nov 03

<a href="https://laohu8.com/S/DNA.WS">Ginkgo Bioworks</a> Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production

Ginkgo Bioworks Holdings Inc. announced that it has been awarded a contract valued at up to $22.2 million through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies for protection against and treatment of infections caused by filoviruses such as Ebola and Sudan viruses. The initiative will focus on producing an anti-filovirus monoclonal antibody cocktail, 1C3 and 1C11, originally developed by Emory University. Ginkgo Bioworks will collaborate with partners including ABL, Isolere Bio by Donaldson, NeuImmune, and ProteoNic to advance biomanufacturing technologies as part of this federally funded project.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE11791) on November 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2580562213"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580562213\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580562213?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580562213","market":"us","top_or_hot":-1,"title":"Ginkgo Bioworks Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DNA.WS\">Ginkgo Bioworks</a> Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks Holdings Inc.</a> announced that it has been awarded a contract valued at up to $22.2 million through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies for protection against and treatment of infections caused by filoviruses such as Ebola and Sudan viruses. The initiative will focus on producing an anti-filovirus monoclonal antibody cocktail, 1C3 and 1C11, originally developed by Emory University. Ginkgo Bioworks will collaborate with partners including ABL, Isolere Bio by Donaldson, NeuImmune, and ProteoNic to advance biomanufacturing technologies as part of this federally funded project.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/DNABW\">Ginkgo Bioworks Holdings Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: NE11791) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ginkgo Bioworks Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGinkgo Bioworks Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-03 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/DNA.WS\">Ginkgo Bioworks</a> Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/DNA\">Ginkgo Bioworks Holdings Inc.</a> announced that it has been awarded a contract valued at up to $22.2 million through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies for protection against and treatment of infections caused by filoviruses such as Ebola and Sudan viruses. The initiative will focus on producing an anti-filovirus monoclonal antibody cocktail, 1C3 and 1C11, originally developed by Emory University. Ginkgo Bioworks will collaborate with partners including ABL, Isolere Bio by Donaldson, NeuImmune, and ProteoNic to advance biomanufacturing technologies as part of this federally funded project.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/DNABW\">Ginkgo Bioworks Holdings Inc.</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: NE11791) on November 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DNA","symbol_name":"Ginkgo Bioworks Holdings Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL2qFrhF:1","article_id":"2580562213","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580562213","pubTimestamp":1762174979,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ginkgo Bioworks Holdings Inc. announced that it has been awarded a contract valued at up to $22.2 million through the Biomedical Advanced Research and Development Authority's  Biopharmaceutical Manufacturing Preparedness Consortium . The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies for protection against and treatment of infections caused by filoviruses such as Ebola and Sudan viruses. The initiative will focus on producing an anti-filovirus monoclonal antibody cocktail, 1C3 and 1C11, originally developed by Emory University. Ginkgo Bioworks will collaborate with partners including ABL, Isolere Bio by Donaldson, NeuImmune, and ProteoNic to advance biomanufacturing technologies as part of this federally funded project.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DNA":"Ginkgo Bioworks Holdings Inc.","BK4161":"工业机械","BK4139":"生物科技","BK4121":"生命科学工具和服务","DCI":"唐纳森","BK4109":"特种化学制品"},"translate_title":"Ginkgo Bioworks赢得价值2220万美元的BARDA抗丝状病毒抗体生产合同","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCI":0.9,"DNA":0.9},"content_text":"Ginkgo Bioworks Wins $22.2 Million BARDA Contract for Anti-Filovirus Antibody Production\n    \n\nGinkgo Bioworks Holdings Inc. announced that it has been awarded a contract valued at up to $22.2 million through the Biomedical Advanced Research and Development Authority's (BARDA) Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium). The project aims to develop innovations to strengthen and reduce the costs of domestic biomanufacturing of monoclonal antibodies for protection against and treatment of infections caused by filoviruses such as Ebola and Sudan viruses. The initiative will focus on producing an anti-filovirus monoclonal antibody cocktail, 1C3 and 1C11, originally developed by Emory University. Ginkgo Bioworks will collaborate with partners including ABL, Isolere Bio by Donaldson, NeuImmune, and ProteoNic to advance biomanufacturing technologies as part of this federally funded project.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE11791) on November 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}